NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) and Artivion (NYSE:AORT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.
Profitability
This table compares NeuroOne Medical Technologies and Artivion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NeuroOne Medical Technologies | -343.55% | -277.71% | -204.28% |
| Artivion | -2.61% | 3.64% | 1.32% |
Analyst Recommendations
This is a summary of current recommendations and price targets for NeuroOne Medical Technologies and Artivion, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NeuroOne Medical Technologies | 0 | 0 | 1 | 0 | 3.00 |
| Artivion | 0 | 0 | 3 | 0 | 3.00 |
Insider and Institutional Ownership
16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 7.5% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 8.1% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings and Valuation
This table compares NeuroOne Medical Technologies and Artivion’s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NeuroOne Medical Technologies | $1.95 million | 12.14 | -$11.86 million | ($0.58) | -1.47 |
| Artivion | $354.00 million | 3.05 | -$30.69 million | ($0.24) | -107.71 |
NeuroOne Medical Technologies has higher earnings, but lower revenue than Artivion. Artivion is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
NeuroOne Medical Technologies has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.
Summary
Artivion beats NeuroOne Medical Technologies on 9 of the 12 factors compared between the two stocks.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.
About Artivion
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
